Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on SAGE Therapeutics (NASDAQ:SAGE) on Thursday, setting a price target of $119, which is approximately 39.93% above the present share price of $85.04.
Kulkarni expects SAGE Therapeutics to post earnings per share (EPS) of -$2.03 for the first quarter of 2021.
The current consensus among 17 TipRanks analysts is for a Moderate Buy rating of shares in SAGE Therapeutics, with an average price target of $94.5.
The analysts price targets range from a high of $121 to a low of $70.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $1.64 million and a net profit of -$107.69 million. The company's market cap is $4.8 billion.
According to TipRanks.com, Canaccord Genuity analyst Sumant Kulkarni is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 22.5% and a 55.96% success rate.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.